ArticleAmerican journal of translational research2026
Shuangshen Ningxin capsules ameliorate diabetic cardiomyopathy in mice by inhibiting ferroptosis via the NRF2/HO-1 signaling pathway.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of Shuangshen Ningxin Capsules (SSNX) on myocardial function in patients with diabetic cardiomyopathy (DCM) and its underlying mechanism.
methodsA streptozotocin (STZ)-induced DCM model was established in C57BL/6J mice. The mice were administered low or high doses of SSNX (90 mg/kg/d or 180 mg/kg/d). Cardiac function was evaluated by echocardiographic parameters, H&E staining, Masson staining, and TUNEL assays. Transcriptomics analysis and Western blotting analysis were performed to explore potential molecular mechanisms. An
resultsSSNX significantly improved cardiac dysfunction and attenuated cardiomyocyte hypertrophy, myocardial fibrosis, and apoptosis in DCM mice. Transcriptomics analysis revealed that after SSNX intervention, 16 originally upregulated genes were downregulated, while 33 originally downregulated genes were upregulated. These differentially expressed genes (DEGs) were associated with ferroptosis-related pathways.
conclusionSSNX alleviates myocardial injury in DCM mice, and the mechanism underlying the effect of SSNX may involve activation of the NRF2/HO-1 signaling pathway to inhibit ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.